Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Metastasis | Research article

Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis

Authors: Chaoran Yu, Yujie Zhang

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

This study aimed to establish nomogram models of overall survival (OS) and cancer-specific survival (CSS) in elderly colorectal cancer (ECRC) patients (Age ≥ 70).

Methods

The clinical variables of patients confirmed as ECRC between 2004 and 2016 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate analysis were performed, followed by the construction of nomograms in OS and CSS.

Results

A total of 44,761 cases were finally included in this study. Both C-index and calibration plots indicated noticeable performance of newly established nomograms. Moreover, nomograms also showed higher outcomes of decision curve analysis (DCA) and the area under the curve (AUC) compared to American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) stage and SEER stage.

Conclusions

This study established nomograms of elderly colorectal cancer patients with distinct clinical values compared to AJCC TNM and SEER stages regarding both OS and CSS.
Literature
1.
Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality [J]. Gut. 2017;66(4):683–91.CrossRef
2.
Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.CrossRef
3.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRef
4.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRef
5.
Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330.CrossRef
6.
De Roock W, De Vriendt V, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer [J]. Lancet Oncol. 2011;12(6):594–603.CrossRef
7.
Lazarus J, Oneka MD, Barua S, et al. Mathematical modeling of the metastatic colorectal cancer microenvironment defines the importance of cytotoxic lymphocyte infiltration and presence of PD-L1 on antigen presenting cells [J]. Ann Surg Oncol. 2019;26(9):2821–30.CrossRef
8.
Edge SB, Compton CC. The American joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.CrossRef
9.
Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL. Colon cancer, version 1. 2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(3):370–98.CrossRef
10.
Devon KM, Vergara-Fernandez O, Victor JC, et al. Colorectal cancer surgery in elderly patients: presentation, treatment, and outcomes [J]. Dis Colon Rectum. 2009;52(7):1272–7.CrossRef
11.
Kennedy AS, Ball DS, Cohen SJ, et al. Safety and efficacy of radioembolization in elderly (≥ 70 years) and younger patients with unresectable liver-dominant colorectal cancer [J]. Clin Colorectal Cancer. 2016;15(2):141–151. e6.CrossRef
12.
Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer [J]. Br J Cancer. 2006;94(7):969–75.CrossRef
13.
Suzuki C, Blomqvist L, Sundin A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy [J]. Ann Oncol. 2012;23(4):948–54.CrossRef
14.
Li Q, Gan L, Liang L, et al. The influence of marital status on stage at diagnosis and survival of patients with colorectal cancer [J]. Oncotarget. 2015;6(9):7339.CrossRef
15.
Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program [J]. Oncologist. 2007;12(1).
16.
Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Prev Biomarkers. 1999;8(12):1117–21.
17.
Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2007;12(1):20–37.CrossRef
18.
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.CrossRef
19.
Kong X, Li J, Cai Y, et al. A modified TNM staging system for non-metastatic colorectal cancer based on nomogram analysis of SEER database [J]. BMC Cancer. 2018;18(1):50.CrossRef
20.
Zhang Z, Luo Q, Yin X, et al. Nomograms to predict survival after colorectal cancer resection without preoperative therapy [J]. BMC Cancer. 2016;16(1):658.CrossRef
21.
Yu C, Zhang Y. Development and validation of a prognostic nomogram for early-onset colon cancer [J]. Biosci Rep. 2019;39(6).
22.
Li D, Zhong C, Tang X, et al. Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy [J]. J Cancer Res Clin Oncol. 2018;144(5):909–23.CrossRef
23.
Tan Z, Zhang M, Han Q, et al. A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the fibrinogen/albumin ratio [J]. J Cancer. 2017;8(6):1025.CrossRef
24.
Zhou H, Tang K, Xiao H, et al. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer [J]. J Exp Clin Cancer Res. 2015;34(1):53.CrossRef
25.
Song K, Shi X, Wang H, et al. Can a nomogram help to predict the overall and cancer-specific survival of patients with chondrosarcoma?[J]. Clin Orthop Relat Res. 2018;476(5):987.CrossRef
26.
Kornprat P, Pollheimer MJ, Lindtner RA, et al. Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal [J]. Am J Clin Oncol. 2011;34(1):43–9.CrossRef
Metadata
Title
Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis
Authors
Chaoran Yu
Yujie Zhang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01464-z

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue

Case report

Asymptomatic hepatic artery dissection early after living-donor liver transplantation with simultaneous splenectomy: two case reports

Research article

A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial

Research article

Increasing newly diagnosed inflammatory bowel disease and improving prognosis in China: a 30-year retrospective study from a single centre

Research article

High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study

Case report

A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy

Research article

Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits